Works matching AU Kristiansen, Nina Sahlertz

Results: 6
    1
    2

    Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.

    Published in:
    Clinical Drug Investigation, 2022, v. 42, n. 4, p. 319, doi. 10.1007/s40261-022-01120-2
    By:
    • Rivero-Ferrer, Elena;
    • Olesen, Morten;
    • Plana, Estel;
    • Aguado, Jaume;
    • Saigí-Morgui, Núria;
    • Rubino, Annalisa;
    • Daoud, Sami Z.;
    • Lei, Alejhandra;
    • Perez-Gutthann, Susana;
    • Schink, Tania;
    • Kristiansen, Nina Sahlertz;
    • Hallas, Jesper;
    • Pottegård, Anton;
    • Rebordosa, Cristina
    Publication type:
    Article
    3

    Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program.

    Published in:
    Pharmacoepidemiology & Drug Safety, 2024, v. 33, n. 5, p. 1, doi. 10.1002/pds.5799
    By:
    • de Vogel, Stefan;
    • Seeger, John D.;
    • Arana, Alejandro;
    • Margulis, Andrea V.;
    • McQuay, Lisa J.;
    • Perez‐Gutthann, Susana;
    • Hallas, Jesper;
    • Kristiansen, Nina Sahlertz;
    • Linder, Marie;
    • Odsbu, Ingvild;
    • Suehs, Brandon;
    • Xu, Yihua;
    • Uribe, Claudia;
    • Appenteng, Kwame;
    • Robinson, Noah Jamie
    Publication type:
    Article
    4

    A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.

    Published in:
    Current Medical Research & Opinion, 2021, v. 37, n. 5, p. 867, doi. 10.1080/03007995.2021.1891035
    By:
    • Phiri, Kelesitse;
    • Hallas, Jesper;
    • Linder, Marie;
    • Margulis, Andrea;
    • Suehs, Brandon;
    • Arana, Alejandro;
    • Bahmanyar, Shahram;
    • Hoffman, Veena;
    • Enger, Cheryl;
    • Horter, Libby;
    • Odsbu, Ingvild;
    • Olesen, Morten;
    • Perez-Gutthann, Susana;
    • Kristiansen, Nina Sahlertz;
    • Appenteng, Kwame;
    • de Vogel, Stefan;
    • Seeger, John
    Publication type:
    Article
    5

    Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

    Published in:
    2021
    By:
    • Hoffman, Veena;
    • Hallas, Jesper;
    • Linder, Marie;
    • Margulis, Andrea V.;
    • Suehs, Brandon T.;
    • Arana, Alejandro;
    • Phiri, Kelesitse;
    • Enger, Cheryl;
    • Horter, Libby;
    • Odsbu, Ingvild;
    • Olesen, Morten;
    • Perez-Gutthann, Susana;
    • Xu, Yihua;
    • Kristiansen, Nina Sahlertz;
    • Appenteng, Kwame;
    • de Vogel, Stefan;
    • Seeger, John D.;
    • the mirabegron PMR-PASS study group;
    • Seeger, John;
    • Bahmanyar, Shahram
    Publication type:
    journal article
    6